Arrowhead (ARWR) Gains 8.52% for June 23

Equities Staff  |

Today, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) was up $2.69 to finish the day Thursday at $34.26.

The company started at $31.75 and shares fluctuated between $34.30 and $31.68 with 899,634 shares trading hands.

Arrowhead is averaging 864,942 shares traded over the last 30 days. They have lost 52.38% YTD.

Arrowhead expects its next earnings on 2022-08-04.

For technical charts, analysis, and more on Arrowhead visit the company profile.

About Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

To get more information on Arrowhead Pharmaceuticals Inc. and to follow the company's latest updates, you can visit the company's profile page here: Arrowhead Pharmaceuticals Inc.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade

Market Movers

Sponsored Financial Content